secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kalaris Therapeutics, Inc. (KLRS)
CIK:        0001754068
Form:       8-K
Filed at:   2025-12-17T23:59:59+00:00
Accession:  0001193125-25-322950
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kalaris Therapeutics reports positive Phase 1a data for TH103 in nAMD; accelerates development
--------------------------------------------------------------------------------

- Mean 10-letter BCVA gain and 129 µm CST improvement at Month 1 across all dose levels (0.5–2.5 mg).
- Mean ~95% reduction in central subfield intraretinal fluid; no dose-limiting toxicities or TH103-related serious AEs.
- Two transient IOI cases at 2.5 mg resolved with manufacturing process change; zero new IOI in 6 subsequent subjects.
- 31% of patients (4/13) required no additional anti-VEGF treatment during the 6-month follow-up after a single injection.
- Plasma Cmax 27–51-fold lower vs. leading anti-VEGF agents; Phase 1b/2 enrollment ongoing, preliminary data expected 2H 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1754068/000119312525322950/0001193125-25-322950-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1754068/000119312525322950/d25416d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-322950

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer